Biohaven Pharmaceutical Holding Company Ltd represents a set of values and corporate philosophy that revolve around developing innovative therapies to improve the lives of patients with neurological and neuropsychiatric diseases. The company is committed to scientific excellence, integrity, and collaboration to drive advancements in the field of neuroscience. Biohaven prioritizes patient-centricity, ensuring access to its therapies and delivering value to stakeholders. With a focus on research and development, Biohaven aims to inspire hope and create a positive impact on the healthcare industry. As a leading pharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd strives to enhance patient outcomes through its commitment to science, integrity, and collaboration.

Biohaven Pharmaceutical Holding Company Ltd is primarily present in the United States.

Biohaven Pharmaceutical Holding Company Ltd has achieved several significant milestones. The company successfully received U.S. FDA approval for their migraine treatment, rimegepant, which brings new hope for patients suffering from migraines. In addition, Biohaven obtained FDA breakthrough therapy designation for their experimental treatment, troriluzole, in spinocerebellar ataxia, a neurodegenerative disorder. The company also secured a global licensing agreement with Bristol Myers Squibb for the development and commercialization of their oral small molecule glutamate modulating agents. These accomplishments highlight Biohaven Pharmaceutical Holding Company Ltd's dedication to advancing innovative therapies to address unmet medical needs.

Biohaven Pharmaceutical Holding Company Ltd is a renowned biopharmaceutical firm that focuses on developing innovative therapies for neurological diseases. Established in 2013, Biohaven has rapidly emerged as a key player in the industry. Their dedicated team of scientists and researchers work diligently to discover and develop new treatments to improve the lives of patients suffering from conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, and migraine. With a commitment to innovation and a strong pipeline of potential therapies, Biohaven Pharmaceutical Holding Company Ltd continues to make significant contributions to the field of neuroscience.

The main competitors of Biohaven Pharmaceutical Holding Company Ltd in the market include pharmaceutical companies such as AbbVie Inc., Eli Lilly and Company, and Johnson & Johnson. These companies are also active in the field of developing and commercializing pharmaceutical products, including therapies for neurological and neurodegenerative disorders. During its market presence, Biohaven Pharmaceutical Holding Company Ltd has demonstrated its ability to compete with these industry giants by innovating and developing unique treatment options. As Biohaven continues to advance its research and development, it strives to maintain a competitive edge within the pharmaceutical market.

Biohaven Pharmaceutical Holding Company Ltd is primarily active in the pharmaceutical industry.

The business model of Biohaven Pharmaceutical Holding Company Ltd is focused on the development and commercialization of innovative therapies to address unmet medical needs. As a pharmaceutical company, Biohaven aims to deliver novel treatments in neurological and neuropsychiatric diseases. Their business model involves conducting research, clinical trials, and seeking regulatory approval for their potential drug candidates. Through strategic partnerships and collaborations, Biohaven aims to bring their promising therapies to the market, benefiting patients worldwide. By combining scientific expertise with a strong commitment to patient care, Biohaven Pharmaceutical Holding Company Ltd strives to make a significant impact in the field of neurology and neurosciences.

Biohaven Pharmaceutical Holding Company KGV ir -3,00.

Biohaven Pharmaceutical Holding Company KUV ir 63,83.

AlleAktien kvalitātes vērtējums Biohaven Pharmaceutical Holding Company ir 2/10.

gaidāmā Biohaven Pharmaceutical Holding Company apgrozījums ir 41,19 milj. USD.

gaidāmā Biohaven Pharmaceutical Holding Company peļņa ir -876,04 milj. USD.

The Biohaven Pharmaceutical Holding Company Ltd is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neurological disorders. It was founded in 2013 and is headquartered in New Haven, Connecticut. Biohaven conducts research and development programs for a variety of diseases, including migraine, Alzheimer's, stroke, schizophrenia, and anxiety disorders. The company's main activities include the discovery and development of drugs based on its proprietary molecules, including small molecules and antibodies. It focuses on developing novel therapies targeting the needs of patients suffering from severe or rare neurological disorders. Biohaven's Piperazine Analog Scale (PAS) and especially the CGRP inhibitor Rimegepant have been successfully tested in Phase III clinical trials for the treatment of migraine. The initial results show a significant improvement in migraine frequency, with average results decreasing from over 4.8 migraine days per month to less than 0.8 days per month for patients, with a risk of side effects of less than 2%. Biohaven's focus is on developing therapies for neurological disorders that have been inadequately treated or have no effective therapy available. In close collaboration with leading neuroscientists and researchers, research and development programs are underway to create novel therapies for Alzheimer's, stroke, and schizophrenia. Biohaven places great emphasis on comprehensive and thorough clinical evaluation. Clinical studies are conducted in close collaboration with experienced clinical researchers and experts to adhere to the highest standards of clinical development. The company also focuses on creating strategic partnerships to further expand and scale its development programs globally. For example, in June 2020, Biohaven signed a partnership with the Chinese pharmaceutical company Royalty Pharma to ensure the distribution and marketing of Rimegepant in the Chinese market. Ultimately, Biohaven aims to provide better care for patients, caregivers, and healthcare providers in neurological disorders with innovative therapies. The company aims to become a leading player in neurology, continuing to grow through its successes in medical research and development.

Biohaven Pharmaceutical Holding Company izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Biohaven Pharmaceutical Holding Company vai uzņēmums nedod dividendes.

Biohaven Pharmaceutical Holding Company ISIN ir VGG111961055.

Biohaven Pharmaceutical Holding Company WKN ir A2DQ7W.

Biohaven Pharmaceutical Holding Company simbols ir BHVN.

Pēdējo 12 mēnešu laikā Biohaven Pharmaceutical Holding Company maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Biohaven Pharmaceutical Holding Company plāno maksāt dividendes 0 USD apmērā.

Biohaven Pharmaceutical Holding Company pašreizējā dividendu rentabilitāte ir .

Biohaven Pharmaceutical Holding Company maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Biohaven Pharmaceutical Holding Company pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Biohaven Pharmaceutical Holding Company tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Biohaven Pharmaceutical Holding Company apmērā 0 USD, kas tika izmaksāta 6.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.09.2024..

Pēdējās dividendes izmaksa notika 6.09.2024..

Gadā 2023, Biohaven Pharmaceutical Holding Company izmaksāja 0 USD dividendes.

Biohaven Pharmaceutical Holding Company dividendes tiek izmaksātas USD.